Eric C. McGary, MD, PhD ...

Dr. Eric C. McGary

Claim this profile

Kaiser Permanente-Anaheim

Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
11 reported clinical trials
19 drugs studied

Area of expertise

1Lung Cancer
Eric C. McGary has run 10 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Non-Small Cell Lung Cancer
Eric C. McGary has run 10 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II

Affiliated Hospitals

Image of trial facility.
Kaiser Permanente-Anaheim
Image of trial facility.
Kaiser Permanente-Fontana

Clinical Trials Eric C. McGary is currently running

Image of trial facility.

Crizotinib

for Non-Small Cell Lung Cancer

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria

More about Eric C. McGary

Clinical Trial Related10 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Eric C. McGary has experience with
  • Pembrolizumab
  • Carboplatin
  • Pemetrexed
  • Ramucirumab
  • Crizotinib
  • Paclitaxel

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Eric C. McGary specialize in?
Is Eric C. McGary currently recruiting for clinical trials?
Are there any treatments that Eric C. McGary has studied deeply?
What is the best way to schedule an appointment with Eric C. McGary?
What is the office address of Eric C. McGary?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security